SPEECH DISORDERS AND THEIR CORRECTION IN POST-STROKE PATIENTS
https://doi.org/10.21518/2079-701X-2017-5-28-32
Abstract
The article is dedicated to the diagnosis, classification, and rehabilitation of various forms of speech disorders in poststroke patients. It is considered the most common types of expressive and impressive speech disorders. The main diagnostic signs of most frequent forms of aphasia and dysarthria are given. A plan for the rehabilitation program with the inclusion of a medication (Ceraxon®) and non-pharmacological methods of correcting speech disorders after stroke is offered.
About the Authors
O. V. Kurushina
Volgograd State Medical University
Russian Federation
MD
Russian Federation
MD
A. E. Barulin
Volgograd State Medical University
Russian Federation
MD
Russian Federation
MD
E. A. Kurakova
Volgograd State Medical University
Russian Federation
Russian Federation
H. Sh. Ansarov
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. Шкловский В.М., Визель Т.Г. Восстановление речевой функции у больных с разными формами афазии. М.: Ассоциация дефектологов, В. Секачев, 2011.
2. Rofes L et al. Neuogenic and oropharyngeal dysphagia. Annals of Тhe NewYork Academy of Sciences. The 11th OESO World Conference: Reflux Disease. 2013, 1300.
3. Alvarez-Sabin J, Roman G. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke, 2011, 42: S40.
4. Клюшников С.А. Нейропротективные и нейрорепаративные эффекты Цераксона (цитиколина): обзор экспериментальных и клинических исследований. Нервные болезни, 2012, 3: 13-20.
5. Hurtado O, Cardenas A et al. A chronic treatment with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol. Dis., 2007, 26: 105-111.
6. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwi-derski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neuro, 2000, 48: 713-722.
7. Secades J. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol, 2011, 52(Suppl 2): S1-S62.
8. Цветкова Л.С. Нейропсихологическая реабилитация больных. Москва – Воронеж, 2004.
9. Holland A & Fridriksson J. Aphasia management during the early phases of recovery following stroke. American Journal of SpeechLanguage Pathology, 2001, 10(1): 19-28.
10. De Jong-Hagelstein M, van de Sandt-Koenderman WM, Prins ND, Dippel DW, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). Journal of Neurology, Neurosurgery, & Psychiatry, 2011, 82: 399-404.
11. Шохор-Троцкая М.К. (Бурлакова). Стратегия и тактика восстановления речи. М.: В. Секачев, Эксмо-Пресс, 2001.
12. Курушина О.В., Барулин А.Е. Жизнь после инсульта: как быть и что делать? РМЖ, 2013, 21(16): 826-830.
13. Галкин А.С., Баранцевич Е.Р. и др. Возможности повышения эффективности реабилитации пациентов после инсульта с синдромом игнорирования. Журнал неврологии и психиатрии им. C.C. Корсакова, 2014, 114(10): 30-34.
14. Ахутина Т.В., Микадзе Ю.В. и др. Логопедическая диагностика и реабилитация пациентов с повреждениями головного мозга в остром периоде. Клинические рекомендации. М., 2014. 46 с.
15. Alvarez-Sabin L, Ortega G, Jacas C, Santamarina E, Maisterra O, Ribo M, Molina C, Quintana M, Román GC. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc. Dis, 2013, 35(2): 146-54.
16. Ueda S, Hasegawa T, Ando K et al. Evaluation of the pharmacological effect of CDP-choline injection in post-stroke hemiplegia. Doubleblind comparative study using the Hemiplegia Function Test (12-grade evaluation method). Strides of Medicine, 1994, 170: 297-314.
Review
For citations:
Kurushina OV, Barulin AE, Kurakova EA, Ansarov HS. SPEECH DISORDERS AND THEIR CORRECTION IN POST-STROKE PATIENTS. Meditsinskiy sovet = Medical Council. 2017;(5):28-32. (In Russ.) https://doi.org/10.21518/2079-701X-2017-5-28-32
Views:
2364
Email this article 